Amneal Pharmaceuticals heads into its August 7 earnings date with options positioning at its most bullish in months, even as the stock quietly built a 24% gain over the past month.
The clearest signal this week is in the options market. The put/call ratio has collapsed to just 0.06 — barely one put contract for every sixteen calls — sitting nearly a standard deviation below its 20-day average of 0.29. That average itself reflects a dramatic rotation: through May and into early June, the PCR was running above 0.80, with peak readings near 1.0. The wholesale shift to call-heavy positioning over the past three weeks marks one of the more pronounced sentiment reversals in recent memory for this name. Borrow conditions reinforce the picture of a diminishing bear case. Short interest is a modest 2.5% of the float, up around 10% over the past month but well below levels that would signal a meaningful short thesis. Cost to borrow has more than halved this week to 0.24% — among the lowest readings of the past six weeks. Availability is extraordinarily loose at more than 6,800%, meaning shares to borrow vastly outnumber shares already borrowed. The lending market is offering no friction to new shorts whatsoever, yet they aren't showing up in size. Positioning overall looks bullish rather than defensive.
The Street is modestly supportive, though not loudly so. The consensus sits at buy, with Barclays maintaining Overweight and nudging its target to $16 in late May, while UBS initiated at Buy with a $19 target back in April. Truist is at Buy with a $17 target. The mean target of $17.25 implies minimal upside from the current $17.05 price, suggesting the Street's constructive stance has largely been priced in by the rally. Valuation has re-rated alongside the stock: the price-to-book has expanded by roughly 29% over the past month to 15.3x, and the PE has moved from the low teens to 16.4x. EPS surprise ranks in the 70th percentile, suggesting the company has a reasonable track record of beating estimates — relevant context with Q2 results eight weeks out. The ORTEX short score sits at 38.8, drifting gently lower over the past two weeks, consistent with the easing short pressure signalled by the borrow data.
Ownership carries one notable data point. BlackRock added more than 10 million shares in the period ended June 30, taking its holding to around 7.7% of shares outstanding — a meaningful incremental position from one of the largest passive and active managers globally. Vanguard entities also appear as fresh or growing holders in recent filings. Against the backdrop of a stock that has doubled off its lows over the past year, that institutional accumulation adds weight to the bullish case being expressed in the options market.
The recent earnings history offers a mixed read on how the stock behaves around results. The last print in May 2026 produced a 3% drop on the day and a 10% decline over the following week. The print before that moved up 2% on the day but still lost ground over five sessions. With the stock now trading roughly 30% above where it was at the time of that May release, the August 7 print becomes the next test of whether the re-rating has fundamental support behind it — and whether the call-heavy options positioning reflects genuine confidence or simply an absence of bears.
See the live data behind this article on ORTEX.
Open AMRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
